A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease

Inclusion Criteria: * Diagnosis of Crohn's disease (CD) of at least 3 months in duration * Have moderate to severe CD as assessed by CDAI, stool frequency, and abdominal pain score, and Simple Endoscopic Score for Crohn's disease (SES-CD). * Demonstrated intolerance or inadequate response to conventional or to biologic therapy for CD Exclusion Criteria: * Current diagnosis of ulcerative colitis or indeterminate colitis * Complications of Crohn's disease that require surgical intervention or confound efficacy assessments * Unstable doses of concomitant Crohn's disease therapy